Impact of extended-course oral nirmatrelvir/ritonavir (Paxlovid) in established Long COVID: Case series and research considerations

BACKGROUND: Prior case series suggest that a 5-day course of oral Paxlovid (nirmatrelvir/ritonavir) benefits some people with Long COVID, within and/or outside of the context of an acute reinfection. To the best of our knowledge, there have been no prior case series of people with Long COVID who hav...

Descripción completa

Detalles Bibliográficos
Autores principales: Cohen, Alison K., Jaudon, Toni Wall, Schurman, Eric M., Kava, Lisa, Vogel, Julia Moore, Haas-Godsil, Julia, Lewis, Daniel, Crausman, Samantha, Leslie, Kate, Bligh, Siobhan Christine, Lizars, Gillian, Davids, JD, Sran, Saniya, Peluso, Michael J., McCorkell, Lisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Journal Experts 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10543503/
https://www.ncbi.nlm.nih.gov/pubmed/37790297
http://dx.doi.org/10.21203/rs.3.rs-3359429/v1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10543503/
https://www.ncbi.nlm.nih.gov/pubmed/37790297
http://dx.doi.org/10.21203/rs.3.rs-3359429/v1

Ejemplares similares